Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; referees: 3 approved]

Maria E. Cabanillas; Mark Zafereo; Michelle D. Williams; Renata Ferrarotto; Ramona Dadu; Neil Gross; G. Brandon Gunn; Heath Skinner; Gilbert Cote; Horiana B. Grosu; Priyanka Iyer; Naifa L. Busaidy

doi:10.12688/f1000research.13124.1

F1000Research (Jan 2018)

Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; referees: 3 approved]

Maria E. Cabanillas,
Mark Zafereo,
Michelle D. Williams,
Renata Ferrarotto,
Ramona Dadu,
Neil Gross,
G. Brandon Gunn,
Heath Skinner,
Gilbert Cote,
Horiana B. Grosu,
Priyanka Iyer,
Naifa L. Busaidy

Affiliations

Maria E. Cabanillas: Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Mark Zafereo: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Michelle D. Williams: Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Renata Ferrarotto: Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 515 Holcombe Blvd, Houston, TX, 77030, USA
Ramona Dadu: Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Neil Gross: Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
G. Brandon Gunn: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Heath Skinner: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Gilbert Cote: Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Horiana B. Grosu: Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Priyanka Iyer: Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
Naifa L. Busaidy: Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

DOI: https://doi.org/10.12688/f1000research.13124.1
Journal volume & issue: Vol. 7

Abstract

Read online

Anaplastic thyroid cancer is a rare and aggressive thyroid cancer with an overall survival measured in months. Because of this poor prognosis and often advanced age at presentation, these patients have traditionally been treated palliatively and referred for hospice. However, recent progress using novel therapies has energized the field, and several promising clinical trials are now available for these patients. This review will highlight this progress and the potential treatments that could pave the way to improved outcomes and quality of life for patients with this disease.

Published in F1000Research

ISSN: 2046-1402 (Online)
Publisher: F1000 Research Ltd
Country of publisher: United Kingdom
LCC subjects: Medicine; Science
Website: https://f1000research.com

About the journal